Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644722 | 1.00 | DUT (0.36) | DUTMAPK1 | |
| SCHEMBL6393715 | 1.00 | DUT (0.36) | DUTMAPK1 | |
| SCHEMBL31644643 | 0.94 | DUT (0.35) | DUTMAPK1 | |
| SCHEMBL31644831 | 0.94 | DUT (0.35) | DUTMAPK1 | |
| SCHEMBL3206063 | 0.94 | DUT (0.35) | DUTMAPK1 | |
| SCHEMBL6379670 | 0.92 | DUT (0.34) | DUT | |
| SCHEMBL11292040 | 0.92 | DUT (0.34) | DUT | |
| SCHEMBL15902883 | 0.92 | DUT (0.34) | DUT | |
| SCHEMBL1313907 | 0.88 | MAPK1 (0.33) | DUTMAPK1 | |
| SCHEMBL1313910 | 0.88 | MAPK1 (0.33) | DUTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213493-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. | 2025-07-03 | — | — | US | disclosed |
| US-12296053-B2 | Nanomaterials comprising triols | BEAM THERAPEUTICS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4540222-A1 | NANOMATERIALS COMPRISING TRIOLS | Beam Therapeutics Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119698406-A | Nanomaterials comprising triols | 比姆医疗股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240252443-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024019936-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10173996-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9714230-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006035301-A2 | ERYTHROMYCIN A DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| EP-1159263-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000050391-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | MERCK & CO., INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10173996-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | DUT 205/4885MAPK1 2685/4885 |
| US-20240252443-A1 | NANOMATERIALS COMPRISING TRIOLS | PNPLA2, LIPA, PHOSPHO1 | DUT 1885/4885MAPK1 4328/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | DUT 1865/4885MAPK1 1810/4885 |
| US-12296053-B2 | Nanomaterials comprising triols | PNPLA2, LIPA, PHOSPHO1 | DUT 1885/4885MAPK1 4328/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | DUT 1865/4885MAPK1 1810/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | DUT 1768/4885MAPK1 1086/4885 |
| US-20250213493-A1 | NANOMATERIALS COMPRISING TRIOLS | PNPLA2, LIPA, PHOSPHO1 | DUT 1885/4885MAPK1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.